Table 4.

Univariable and multivariable analyses of factors associated with death and relapse for the 665 granulomatosis with polyangiitis antineutrophil cytoplasm antibody-positive patients

Factor	Death				Relapse
	Univariable analysis		Multivariable analysis		Univariable analysis
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age	1.07 (1.04 to 1.09)	<0.001	1.07 (1.04 to 1.09)	<0.001	1.00 (0.80 to 1.24)	0.999
Female	0.58 (0.33 to 1.02)	0.061			0.99 (099 to 1.00)	0.561
Lung	1.62 (0.85 to 3.07)	0.141			0.98 (0.78 to 1.24)	0.921
Alveolar haemorrhage	2.10 (1.17 to 3.78)	0.012			1.06 (0.80 to 1.40)	0.665
Renal	3.32 (1.71 to 6.45)	0.0001			1.03 (0.77 to 1.20)	0.744
Serum creatinine >150 µmol/L	1.87 (1.03 to 3.38)	0.038			0.86 (0.65 to 1.13)	0.292
Haemodialysis	3.37 (1.51 to 7.53)	0.003			1.31 (0.83 to 2.06)	0.240
Skin	1.42 (0.82 to 2.47)	0.206			1.01 (0.78 to 1.24)	0.912
Ear, nose and throat	0.77 (0.42 to 1.41)	0.409			1.11 (0.84 to 1.45)	0.445
Eye	0.74 (0.39 to 1.38)	0.349			1.08 (0.85 to 1.36)	0.513
Cardiovascular	2.52 (1.40 to 4.53)	0.001			1.03 (0.76 to 1.38)	0.838
Congestive heart failure	9.57 (3.77 to 24.3)	<0.0001	4.58 (1.79 to 11.70)	0.001	0.70 (0.22 to 2.19)	0.547
Gastrointestinal	0.98 (0.35 to 2.74)	0.976			0.87 (0.59 to 1.30)	0.521
Neurological	1.43 (0.82 to 1.48)	0.205			1.00 (0.79 to 1.27)	0.949
Birmingham Vasculitis Activity Score	1.07 (1.03 to 1.10)	<0.001			0.99 (0.97 to 1.00)	0.169
Anti-myeloperoxidase	2.33 (1.31 to 4.14)	0.003			0.80 (0.60 to 1.12)	0.159
Anti-proteinase-3	0.39 (0.22 to 0.70)	0.001	0.43 (0.18 to 1.03)	0.057	1.28 (0.93 to 1.75)	0.119
Intravenous cyclophosphamide	–	–			0.85 (0.64 to 1.11)	0.244
Oral cyclophosphamide	–	–			0.72 (0.40 to 1.28)	0.267
Rituximab	–	–			0.73 (0.40 to 1.34)	0.319
Methotrexate	–	–			1.1 (0.65 to 1.84)	0.719